Research from Papazoglou et al. highlights the substantial risk of atherosclerosis progression and incident cardiovascular events in patients with systemic lupus erythematosus, as well as the importance of prolonged remission and the sustained control of cardiovascular risk factors in mitigating these risks over time.
Lupus Nephritis: A Brief Review
Among patients with systemic lupus erythematosus (SLE), lupus nephritis is one of the more common health problems and a leading cause of mortality. In adults with SLE, as many as five of 10 will develop kidney disease. In children with lupus, eight of 10 will develop kidney disease.1 Lupus nephritis appears to be more prevalent…
How to Recognize Inborn Errors of Immunity
Inborn errors of immunity may not always be easy to recognize, but rheumatologists should look out for them. Dr. Bharat Kumar shares his insights.
ACR Image Competition 2024 Results, Part 6
For the 2024 Image Competition, the ACR sought images with educational or remarkable manifestations representing a diverse range of pediatric patients with autoimmune, inflammatory, infectious and malignant drivers of rheumatic disease. Here, we showcase the winning images from South Asia.
Abatacept Shows Promise for Some Myositis Patients
Injected abatacept may be a worthwhile treatment for certain patients with idiopathic inflammatory myositis (IIM), according to recent research.1 Patients with the rare autoimmune conditions involving inflammation of muscle (myositis) and other organ systems suffer widespread organ dysfunction, increased morbidity, physical disabilities and early death. Symptoms vary by subtype. For example, dermatomyositis (DM) involves muscle…
3 AC&R Study Summaries: SLE Mortality Risk, Heart Failure & RA, & a Phone-Based Walking Program
Risk of Mortality from SLE By Ansaam Daoud, MD, Loai Dweik, MD, & Omer Pamuk, MD Why was this study done? Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with significant mortality, particularly affecting racial and ethnic minorities. This study aimed to assess national SLE mortality trends over the past two decades, stratified by…
SAP-001 Promising for Refractory Gout
Initial findings from a phase 2b clinical trial demonstrate the safety and efficacy of three different daily doses of SAP-001 to lower the serum urate levels of patients with refractory gout.
Cilnidipine Receives Orphan Drug Status to Treat Systemic Sclerosis
Based on research showing improved signs and symptoms of systemic sclerosis in patients taking cilnidipine vs. placebo, the FDA granted orphan drug designation for the agent.
Nipocalimab Receives Breakthrough Therapy Status for Sjögren’s Disease
Nipocalimab, an investigational monoclonal antibody that blocks FcRn and reduces levels of circulating immunoglobulin G (IgG) antibodies, has received the FDA’s breakthrough therapy designation for the treatment of Sjögren’s disease.
Can Stem Cell Transplantation Improve Survival Rates in Patients with Systemic Sclerosis?
Autologous hematopoietic stem cell transplantation (AHSCT) may improve the survival rate of patients with diffuse cutaneous systemic sclerosis (SSc), according to Georges et al. The single-arm clinical trial demonstrated the effectiveness of AHSCT and maintenance therapy. Researchers also identified potential risk factor of AHSCT in patients with low eGFR before transplantation.
- 1
- 2
- 3
- …
- 338
- Next Page »